Royalty Pharma Plc Cl A (RPRX)

$59.69 +0.24 (0.40%)
Market Cap 34.18B
Revenue (ttm) 2.38B
Net Income (ttm) 770.95M
EPS (ttm) N/A
PE Ratio 11.16
Forward PE 11.06
Profit Margin 32.42%
Debt to Equity Ratio 0.92
Volume 2,075,100
Avg Vol 3,120,932
Day's Range N/A - N/A
Shares Out 575.00M
Stochastic %K 81%
Beta 0.43
Analysts Strong Sell
Price Target $64.14

Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ...

Industry: Biotechnology
Sector: Healthcare
Phone: 212 883 0200
Address:
110 East 59th Street, New York, United States
Doozio
Doozio Aug. 19 at 12:54 AM
$RPRX obviously.
0 · Reply
Doozio
Doozio Aug. 19 at 12:53 AM
$RPRX how many sell signals this 🧠leader🐑 have? Then why YO sell it? Bums.
0 · Reply
fda_tracker
fda_tracker Aug. 7 at 3:00 PM
$RPRX New PDUFA Date 2027-04-23 Royalty Pharma plc Link: https://www.sec.gov/Archives/edgar/data/1802768/000180276826000014/rprx-20260630rpplcpressxre.htm Calendar: http://www.fdatracker.com/fda-calendar/
0 · Reply
fda_tracker
fda_tracker Aug. 7 at 3:00 PM
$RPRX New PDUFA Date 2026-11-27 Royalty Pharma plc Link: https://www.sec.gov/Archives/edgar/data/1802768/000180276826000014/rprx-20260630rpplcpressxre.htm Calendar: http://www.fdatracker.com/fda-calendar/
0 · Reply
EarningsInsider
EarningsInsider Aug. 5 at 1:46 PM
https://www.marketbeat.com/earnings/reports/2026-8-5-royalty-pharma-plc-stock/ $RPRX Royalty Pharma Earnings Transcript
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Aug. 5 at 11:40 AM
$RPRX Q2 '26 Earnings Results & Recap • Reported GAAP EPS of $0.03 down -57.14% YoY • Reported revenue of $674M up 16.47% YoY • Royalty Pharma raised its full year 2026 guidance for Portfolio Receipts to between $3,400 million and $3,500 million, representing expected Royalty Receipts growth of 7% to 10% for Royalty Pharma.
0 · Reply
GabrielBarrett973
GabrielBarrett973 Aug. 5 at 5:31 AM
$EQT $EXR $RPRX $NTR $CCI EQT benefits from natural gas demand, Extra Space Storage leads self-storage, Royalty Pharma generates pharmaceutical royalties, Nutrien benefits from agriculture, and Crown Castle dominates communications infrastructure.
0 · Reply
RobertMickey186
RobertMickey186 Aug. 3 at 2:46 PM
$EQT $EXR $RPRX $NTR $CCI EQT benefits from natural gas demand, Extra Space Storage leads self-storage, Royalty Pharma generates pharmaceutical royalties, Nutrien benefits from agriculture, and Crown Castle dominates communications infrastructure.
0 · Reply
DidYouReadThis
DidYouReadThis Jul. 31 at 4:07 PM
$RPRX $SYNC $XBI $LABU
0 · Reply
Alphatrades09
Alphatrades09 Jul. 29 at 2:51 PM
$RPRX 65C 8/21 @ 0.00 here
0 · Reply
Latest News on RPRX
Zealand Pharma enters $100M royalty purchase, sale pact with Royalty Pharma

2026-08-17T08:40:13.000Z - 2 days ago

Zealand Pharma enters $100M royalty purchase, sale pact with Royalty Pharma

Royalty Pharma and Zealand Pharma enter into rusfertide funding agreement for $100 million

Aug 12, 2026, 4:10 PM EDT - 6 days ago

Royalty Pharma and Zealand Pharma enter into rusfertide funding agreement for $100 million

Zealand Pharma enters into a USD 100 million royalty purchase and sale agreement with Royalty Pharma for the economics related to rusfertide

Aug 12, 2026, 4:05 PM EDT - 6 days ago

Zealand Pharma enters into a USD 100 million royalty purchase and sale agreement with Royalty Pharma for the economics related to rusfertide

Royalty Pharma Slides: Corporate presentation

Aug 11, 2026, 8:00 AM EDT - 8 days ago

Royalty Pharma Slides: Corporate presentation

Royalty Pharma price target raised to $66 from $59 at Goldman Sachs

2026-08-06T13:41:15.000Z - 12 days ago

Royalty Pharma price target raised to $66 from $59 at Goldman Sachs

Royalty Pharma price target raised to $65 from $64 at Morgan Stanley

2026-08-06T11:52:44.000Z - 13 days ago

Royalty Pharma price target raised to $65 from $64 at Morgan Stanley

Royalty Pharma price target raised to $70 from $66 at Citi

2026-08-06T10:41:43.000Z - 13 days ago

Royalty Pharma price target raised to $70 from $66 at Citi

Royalty Pharma Earnings Call Transcript: Q2 2026

Aug 5, 2026, 8:00 AM EDT - 14 days ago

Royalty Pharma Earnings Call Transcript: Q2 2026

Royalty Pharma Earnings release: Q2 2026

Aug 5, 2026, 8:00 AM EDT - 14 days ago

Royalty Pharma Earnings release: Q2 2026

Royalty Pharma Slides: Q2 2026

Aug 5, 2026, 8:00 AM EDT - 14 days ago

Royalty Pharma Slides: Q2 2026

Royalty Pharma Quarterly report: Q2 2026

Aug 5, 2026, 8:00 AM EDT - 14 days ago

Royalty Pharma Quarterly report: Q2 2026

Royalty Pharma reports Q2 revenue $647M, consensus $758.88M

2026-08-05T11:46:23.000Z - 14 days ago

Royalty Pharma reports Q2 revenue $647M, consensus $758.88M

Royalty Pharma reports second quarter 2026 results

Aug 5, 2026, 7:00 AM EDT - 14 days ago

Royalty Pharma reports second quarter 2026 results

Royalty Pharma appoints Greg Raskin as Senior Vice President, Head of Academic Initiatives

Aug 3, 2026, 8:15 AM EDT - 16 days ago

Royalty Pharma appoints Greg Raskin as Senior Vice President, Head of Academic Initiatives

Royalty Pharma buys royalty interest in AstraZeneca cliramitug for $125M upfront

2026-07-22T11:36:39.000Z - 4 weeks ago

Royalty Pharma buys royalty interest in AstraZeneca cliramitug for $125M upfront

AZN

Royalty Pharma acquires royalty interest in AstraZeneca's cliramitug for up to $425 million from Neurimmune

Jul 22, 2026, 7:05 AM EDT - 4 weeks ago

Royalty Pharma acquires royalty interest in AstraZeneca's cliramitug for up to $425 million from Neurimmune

Royalty Pharma declares third quarter 2026 dividend

Jul 17, 2026, 4:15 PM EDT - 4 weeks ago

Royalty Pharma declares third quarter 2026 dividend

Royalty Pharma to announce second quarter 2026 financial results on August 5, 2026

Jul 15, 2026, 4:15 PM EDT - 4 weeks ago

Royalty Pharma to announce second quarter 2026 financial results on August 5, 2026

Royalty Pharma price target raised to $65 from $50 at TD Cowen

2026-07-13T13:10:13.000Z - 5 weeks ago

Royalty Pharma price target raised to $65 from $50 at TD Cowen

Royalty Pharma Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 9, 2026, 4:00 PM EDT - 2 months ago

Royalty Pharma Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Royalty Pharma to present at the Goldman Sachs 47th Annual Global Healthcare Conference

Jun 4, 2026, 4:15 PM EDT - 2 months ago

Royalty Pharma to present at the Goldman Sachs 47th Annual Global Healthcare Conference

Royalty Pharma Transcript: RBC Capital Markets Global Healthcare Conference 2026

May 19, 2026, 10:00 AM EDT - 3 months ago

Royalty Pharma Transcript: RBC Capital Markets Global Healthcare Conference 2026

Royalty Pharma Transcript: Bank of America Global Healthcare Conference 2026

May 13, 2026, 1:40 PM EDT - 3 months ago

Royalty Pharma Transcript: Bank of America Global Healthcare Conference 2026

Royalty Pharma Slides: Corporate presentation

May 11, 2026, 7:00 AM EDT - 3 months ago

Royalty Pharma Slides: Corporate presentation

Royalty Pharma to present at upcoming investor conferences

May 7, 2026, 4:15 PM EDT - 3 months ago

Royalty Pharma to present at upcoming investor conferences

Royalty Pharma price target raised to $64 from $63 at Morgan Stanley

2026-05-07T19:05:03.000Z - 3 months ago

Royalty Pharma price target raised to $64 from $63 at Morgan Stanley

Royalty Pharma price target raised to $58 from $50 at JPMorgan

2026-05-07T15:26:17.000Z - 3 months ago

Royalty Pharma price target raised to $58 from $50 at JPMorgan

Royalty Pharma price target raised to $66 from $50 at Citi

2026-05-07T11:16:52.000Z - 3 months ago

Royalty Pharma price target raised to $66 from $50 at Citi

Royalty Pharma Earnings Call Transcript: Q1 2026

May 6, 2026, 8:00 AM EDT - 3 months ago

Royalty Pharma Earnings Call Transcript: Q1 2026

Royalty Pharma Earnings release: Q1 2026

May 6, 2026, 8:00 AM EDT - 3 months ago

Royalty Pharma Earnings release: Q1 2026

Royalty Pharma Slides: Q1 2026

May 6, 2026, 8:00 AM EDT - 3 months ago

Royalty Pharma Slides: Q1 2026

Royalty Pharma Quarterly report: Q1 2026

May 6, 2026, 8:00 AM EDT - 3 months ago

Royalty Pharma Quarterly report: Q1 2026

Royalty Pharma reports first quarter 2026 results

May 6, 2026, 7:00 AM EDT - 3 months ago

Royalty Pharma reports first quarter 2026 results

An 8-Hour AI Result Is Testing Pharma's $10 Billion Royalty Market

May 1, 2026, 12:00 PM EDT - 3 months ago

An 8-Hour AI Result Is Testing Pharma's $10 Billion Royalty Market

Royalty Pharma Launches Global Translational Prize to Recognize Breakthrough Scientific Innovation

Apr 21, 2026, 1:00 PM EDT - 4 months ago

Royalty Pharma Launches Global Translational Prize to Recognize Breakthrough Scientific Innovation

Royalty Pharma price target raised to $57 from $51 at UBS

2026-04-21T12:29:12.000Z - 4 months ago

Royalty Pharma price target raised to $57 from $51 at UBS

Royalty Pharma Declares Second Quarter 2026 Dividend

Apr 17, 2026, 8:30 AM EDT - 4 months ago

Royalty Pharma Declares Second Quarter 2026 Dividend

Royalty Pharma to Announce First Quarter 2026 Financial Results on May 6, 2026

Apr 15, 2026, 4:15 PM EDT - 4 months ago

Royalty Pharma to Announce First Quarter 2026 Financial Results on May 6, 2026

Royalty Pharma price target raised to $63 from $61 at Morgan Stanley

2026-04-10T13:01:22.000Z - 4 months ago

Royalty Pharma price target raised to $63 from $61 at Morgan Stanley

Royalty Pharma Proxy statement: Proxy filing

Apr 10, 2026, 8:00 AM EDT - 4 months ago

Royalty Pharma Proxy statement: Proxy filing

Royalty Pharma Proxy statement: Proxy filing

Apr 10, 2026, 8:00 AM EDT - 4 months ago

Royalty Pharma Proxy statement: Proxy filing

Royalty Pharma and J&J partner to develop autoimmune treatment

Mar 30, 2026, 9:14 AM EDT - 5 months ago

Royalty Pharma and J&J partner to develop autoimmune treatment

JNJ

Royalty Pharma reports co-funding agreement with Johnson & Johnson for JNJ-4804

2026-03-30T11:37:52.000Z - 5 months ago

Royalty Pharma reports co-funding agreement with Johnson & Johnson for JNJ-4804

JNJ

Royalty Pharma Announces R&D Funding Collaboration for Chronic Immune-Mediated Diseases

Mar 30, 2026, 7:15 AM EDT - 5 months ago

Royalty Pharma Announces R&D Funding Collaboration for Chronic Immune-Mediated Diseases

Royalty Pharma Slides: Corporate presentation

Mar 26, 2026, 8:00 AM EDT - 5 months ago

Royalty Pharma Slides: Corporate presentation

Royalty Pharma Appoints Lucas Glass as Head of Artificial Intelligence

Mar 23, 2026, 7:15 AM EDT - 5 months ago

Royalty Pharma Appoints Lucas Glass as Head of Artificial Intelligence

Royalty Pharma Announces Expansion of Leadership Team

Mar 17, 2026, 4:01 PM EDT - 5 months ago

Royalty Pharma Announces Expansion of Leadership Team

Zymeworks price target raised to $48 from $33 at Evercore ISI

2026-03-09T12:10:52.000Z - 5 months ago

Zymeworks price target raised to $48 from $33 at Evercore ISI

ZYME

Royalty Pharma Transcript: TD Cowen 46th Annual Health Care Conference

Mar 3, 2026, 1:10 PM EST - 6 months ago

Royalty Pharma Transcript: TD Cowen 46th Annual Health Care Conference

Royalty Pharma appoints Kenneth Sun as Senior Vice President, Head of Asia

2026-03-02T12:16:19.000Z - 6 months ago

Royalty Pharma appoints Kenneth Sun as Senior Vice President, Head of Asia

Royalty Pharma Appoints Kenneth Sun as Senior Vice President and Head of Asia to Expand Royalty Pharma's Global Platform

Mar 2, 2026, 7:00 AM EST - 6 months ago

Royalty Pharma Appoints Kenneth Sun as Senior Vice President and Head of Asia to Expand Royalty Pharma's Global Platform

Zymeworks, Royalty Pharma enter $250M royalty-backed note financing

2026-03-02T11:15:10.000Z - 6 months ago

Zymeworks, Royalty Pharma enter $250M royalty-backed note financing

JAZZ ONC ZYME

Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing

Mar 2, 2026, 6:10 AM EST - 6 months ago

Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing

Royalty Pharma price target raised to $50 from $45 at TD Cowen

2026-02-27T18:55:35.000Z - 6 months ago

Royalty Pharma price target raised to $50 from $45 at TD Cowen

Royalty Pharma to Present at TD Cowen's 46th Annual Health Care Conference

Feb 26, 2026, 4:15 PM EST - 6 months ago

Royalty Pharma to Present at TD Cowen's 46th Annual Health Care Conference

Royalty Pharma price target raised to $51 from $45 at Goldman Sachs

2026-02-12T13:38:41.000Z - 6 months ago

Royalty Pharma price target raised to $51 from $45 at Goldman Sachs

Royalty Pharma Earnings Call Transcript: Q4 2025

Feb 11, 2026, 8:00 AM EST - 6 months ago

Royalty Pharma Earnings Call Transcript: Q4 2025

Royalty Pharma Annual report: Q4 2025

Feb 11, 2026, 8:00 AM EST - 6 months ago

Royalty Pharma Annual report: Q4 2025

Royalty Pharma Earnings release: Q4 2025

Feb 11, 2026, 8:00 AM EST - 6 months ago

Royalty Pharma Earnings release: Q4 2025

Royalty Pharma Slides: Q4 2025

Feb 11, 2026, 8:00 AM EST - 6 months ago

Royalty Pharma Slides: Q4 2025

Royalty Pharma Reports Q4 and Full Year 2025 Results

Feb 11, 2026, 7:00 AM EST - 6 months ago

Royalty Pharma Reports Q4 and Full Year 2025 Results

Royalty Pharma to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026

Jan 20, 2026, 4:15 PM EST - 7 months ago

Royalty Pharma to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026

Royalty Pharma Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 12:45 PM EST - 7 months ago

Royalty Pharma Transcript: 44th Annual J.P. Morgan Healthcare Conference

Royalty Pharma Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 12:45 PM EST - 7 months ago

Royalty Pharma Slides: 44th Annual J.P. Morgan Healthcare Conference

Royalty Pharma to Highlight Accomplishments and Provide Business Update at 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 7:15 AM EST - 7 months ago

Royalty Pharma to Highlight Accomplishments and Provide Business Update at 44th Annual J.P. Morgan Healthcare Conference

Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

Jan 11, 2026, 5:15 PM EST - 7 months ago

Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

Royalty Pharma Announces Dividend Increase

Jan 9, 2026, 8:30 AM EST - 7 months ago

Royalty Pharma Announces Dividend Increase

Royalty Pharma Acquires Remaining Royalty Interest in Roche's Evrysdi for $240 Million and Potential Milestones

Dec 29, 2025, 4:40 PM EST - 8 months ago

Royalty Pharma Acquires Remaining Royalty Interest in Roche's Evrysdi for $240 Million and Potential Milestones

Royalty Pharma Acquires Royalty Interest in Nuvalent's Neladalkib and Zidesamtinib for Up to $315 Million

Dec 16, 2025, 7:15 AM EST - 8 months ago

Royalty Pharma Acquires Royalty Interest in Nuvalent's Neladalkib and Zidesamtinib for Up to $315 Million

Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement

Dec 4, 2025, 7:10 AM EST - 9 months ago

Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement

Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement

Dec 4, 2025, 7:00 AM EST - 9 months ago

Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement

DNLI

Royalty Pharma Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 3, 2025, 3:50 PM EST - 9 months ago

Royalty Pharma Transcript: Evercore ISI 8th Annual HealthCONx Conference

Royalty Pharma Transcript: Citi Annual Global Healthcare Conference 2025

Dec 2, 2025, 3:15 PM EST - 9 months ago

Royalty Pharma Transcript: Citi Annual Global Healthcare Conference 2025

Royalty Pharma to Present at Upcoming Investor Conferences

Nov 26, 2025, 8:15 AM EST - 9 months ago

Royalty Pharma to Present at Upcoming Investor Conferences

Royalty Pharma Earnings Call Transcript: Q3 2025

Nov 5, 2025, 8:00 AM EST - 10 months ago

Royalty Pharma Earnings Call Transcript: Q3 2025

Royalty Pharma Quarterly report: Q3 2025

Nov 5, 2025, 8:00 AM EST - 10 months ago

Royalty Pharma Quarterly report: Q3 2025

Royalty Pharma Earnings release: Q3 2025

Nov 5, 2025, 8:00 AM EST - 10 months ago

Royalty Pharma Earnings release: Q3 2025

Royalty Pharma Slides: Q3 2025

Nov 5, 2025, 8:00 AM EST - 10 months ago

Royalty Pharma Slides: Q3 2025

Royalty Pharma Reports Third Quarter 2025 Results

Nov 5, 2025, 7:00 AM EST - 10 months ago

Royalty Pharma Reports Third Quarter 2025 Results

Royalty Pharma Acquires Royalty Interest in Alnylam's AMVUTTRA for $310 Million from Blackstone Life Sciences

Nov 4, 2025, 7:15 AM EST - 10 months ago

Royalty Pharma Acquires Royalty Interest in Alnylam's AMVUTTRA for $310 Million from Blackstone Life Sciences

Royalty Pharma Declares Fourth Quarter 2025 Dividend

Oct 17, 2025, 8:15 AM EDT - 10 months ago

Royalty Pharma Declares Fourth Quarter 2025 Dividend

Royalty Pharma to Announce Third Quarter 2025 Financial Results on November 5, 2025

Oct 9, 2025, 4:15 PM EDT - 11 months ago

Royalty Pharma to Announce Third Quarter 2025 Financial Results on November 5, 2025

Royalty Pharma Appoints Dr. Ted W. Love As Lead Independent Director

Sep 29, 2025, 8:15 AM EDT - 11 months ago

Royalty Pharma Appoints Dr. Ted W. Love As Lead Independent Director

Royalty Pharma Transcript: Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum

Sep 23, 2025, 2:50 PM EDT - 11 months ago

Royalty Pharma Transcript: Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum

Royalty Pharma to Present at Bernstein's 2nd Annual Healthcare Forum

Sep 19, 2025, 4:25 PM EDT - 11 months ago

Royalty Pharma to Present at Bernstein's 2nd Annual Healthcare Forum

Royalty Pharma Transcript: Investor Day 2025

Sep 11, 2025, 8:30 AM EDT - 1 year ago

Royalty Pharma Transcript: Investor Day 2025

Royalty Pharma Press release: FY 2025

Sep 11, 2025, 8:30 AM EDT - 1 year ago

Royalty Pharma Press release: FY 2025

Royalty Pharma Slides: FY 2025

Sep 11, 2025, 8:30 AM EDT - 1 year ago

Royalty Pharma Slides: FY 2025

Royalty Pharma Investor Day Highlights Strong Growth Outlook and Company's Plans to Drive Value Creation

Sep 11, 2025, 7:00 AM EDT - 1 year ago

Royalty Pharma Investor Day Highlights Strong Growth Outlook and Company's Plans to Drive Value Creation

Royalty Pharma Announces Release of Deloitte's Report on the Biopharma Royalty Market

Sep 10, 2025, 7:30 AM EDT - 1 year ago

Royalty Pharma Announces Release of Deloitte's Report on the Biopharma Royalty Market

Royalty Pharma Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 9, 2025, 3:20 PM EDT - 1 year ago

Royalty Pharma Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Royalty Pharma to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 4, 2025, 4:15 PM EDT - 1 year ago

Royalty Pharma to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

Royalty Pharma Announces Pricing of $2.0 Billion of Senior Unsecured Notes

Sep 2, 2025, 8:30 PM EDT - 1 year ago

Royalty Pharma Announces Pricing of $2.0 Billion of Senior Unsecured Notes

Royalty Pharma and Zenas BioPharma Enter Into Obexelimab Funding Agreement for Up to $300 Million

Sep 2, 2025, 7:15 AM EDT - 1 year ago

Royalty Pharma and Zenas BioPharma Enter Into Obexelimab Funding Agreement for Up to $300 Million

Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million

Sep 2, 2025, 7:05 AM EDT - 1 year ago

Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million

ZBIO

Royalty Pharma to buy royalty interest in Amgen's lung cancer drug for up to $950 million

Aug 25, 2025, 6:33 AM EDT - 1 year ago

Royalty Pharma to buy royalty interest in Amgen's lung cancer drug for up to $950 million

AMGN

Royalty Pharma to Acquire Royalty Interest in Amgen's Imdelltra for up to $950 Million

Aug 25, 2025, 6:10 AM EDT - 1 year ago

Royalty Pharma to Acquire Royalty Interest in Amgen's Imdelltra for up to $950 Million

BeOne Medicines Announces IMDELLTRA Royalty Purchase Agreement for up to $950 Million

Aug 25, 2025, 6:00 AM EDT - 1 year ago

BeOne Medicines Announces IMDELLTRA Royalty Purchase Agreement for up to $950 Million

ONC

Henry Fernandez Steps Down from Royalty Pharma's Board of Directors

Aug 13, 2025, 4:15 PM EDT - 1 year ago

Henry Fernandez Steps Down from Royalty Pharma's Board of Directors

Royalty Pharma Earnings Call Transcript: Q2 2025

Aug 6, 2025, 8:00 AM EDT - 1 year ago

Royalty Pharma Earnings Call Transcript: Q2 2025

Royalty Pharma Quarterly report: Q2 2025

Aug 6, 2025, 8:00 AM EDT - 1 year ago

Royalty Pharma Quarterly report: Q2 2025

Royalty Pharma Earnings release: Q2 2025

Aug 6, 2025, 8:00 AM EDT - 1 year ago

Royalty Pharma Earnings release: Q2 2025

Royalty Pharma Slides: Q2 2025

Aug 6, 2025, 8:00 AM EDT - 1 year ago

Royalty Pharma Slides: Q2 2025

Royalty Pharma Reports Second Quarter 2025 Results

Aug 6, 2025, 7:00 AM EDT - 1 year ago

Royalty Pharma Reports Second Quarter 2025 Results

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

Aug 1, 2025, 8:31 AM EDT - 1 year ago

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

ABBV ABT ALNY AMGN ARGX AZN BAX

Doozio
Doozio Aug. 19 at 12:54 AM
$RPRX obviously.
0 · Reply
Doozio
Doozio Aug. 19 at 12:53 AM
$RPRX how many sell signals this 🧠leader🐑 have? Then why YO sell it? Bums.
0 · Reply
fda_tracker
fda_tracker Aug. 7 at 3:00 PM
$RPRX New PDUFA Date 2027-04-23 Royalty Pharma plc Link: https://www.sec.gov/Archives/edgar/data/1802768/000180276826000014/rprx-20260630rpplcpressxre.htm Calendar: http://www.fdatracker.com/fda-calendar/
0 · Reply
fda_tracker
fda_tracker Aug. 7 at 3:00 PM
$RPRX New PDUFA Date 2026-11-27 Royalty Pharma plc Link: https://www.sec.gov/Archives/edgar/data/1802768/000180276826000014/rprx-20260630rpplcpressxre.htm Calendar: http://www.fdatracker.com/fda-calendar/
0 · Reply
EarningsInsider
EarningsInsider Aug. 5 at 1:46 PM
https://www.marketbeat.com/earnings/reports/2026-8-5-royalty-pharma-plc-stock/ $RPRX Royalty Pharma Earnings Transcript
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Aug. 5 at 11:40 AM
$RPRX Q2 '26 Earnings Results & Recap • Reported GAAP EPS of $0.03 down -57.14% YoY • Reported revenue of $674M up 16.47% YoY • Royalty Pharma raised its full year 2026 guidance for Portfolio Receipts to between $3,400 million and $3,500 million, representing expected Royalty Receipts growth of 7% to 10% for Royalty Pharma.
0 · Reply
GabrielBarrett973
GabrielBarrett973 Aug. 5 at 5:31 AM
$EQT $EXR $RPRX $NTR $CCI EQT benefits from natural gas demand, Extra Space Storage leads self-storage, Royalty Pharma generates pharmaceutical royalties, Nutrien benefits from agriculture, and Crown Castle dominates communications infrastructure.
0 · Reply
RobertMickey186
RobertMickey186 Aug. 3 at 2:46 PM
$EQT $EXR $RPRX $NTR $CCI EQT benefits from natural gas demand, Extra Space Storage leads self-storage, Royalty Pharma generates pharmaceutical royalties, Nutrien benefits from agriculture, and Crown Castle dominates communications infrastructure.
0 · Reply
DidYouReadThis
DidYouReadThis Jul. 31 at 4:07 PM
$RPRX $SYNC $XBI $LABU
0 · Reply
Alphatrades09
Alphatrades09 Jul. 29 at 2:51 PM
$RPRX 65C 8/21 @ 0.00 here
0 · Reply
Scatpack22
Scatpack22 Jul. 28 at 8:13 PM
$RPRX There’s something about these royalty companies, whether in pharma or oil & gas or gold with their massive opening margins and the revenue per employee. Gotta believe if interest rates get cut this is gonna benefit like biotechs. Time to take a position
0 · Reply
Stocktwits52wHighs
Stocktwits52wHighs Jul. 24 at 7:31 PM
$RPRX printed a new 52-week high today
0 · Reply
Davidendz
Davidendz Jul. 17 at 2:25 PM
$BVAXF $BIOV.CSE $BVAXF is pursuing an out-licensing model, which could reduce internal commercialization requirements. The tradeoff is dependence on partner interest, deal structure and milestone execution. $LGND $RPRX $MRNA
0 · Reply
JFDI
JFDI Jul. 15 at 7:21 PM
$RPRX wow
0 · Reply
MaverikIT
MaverikIT Jul. 9 at 4:57 PM
@Jblack500 @No_Face_character @WAJeff @BustaCapital @cynicaloptimist @IsabellaDC $RPRX $TGTX ... bio$ some new 52wk$ https://finviz.com/screener?v=211&o=-perfytd&t=DNLI%2CMIRM%2CNGNE%2CNKTX%2CPCTC%2CRPRX%2CNBIX%2CTGTX
0 · Reply
VeltrixCapitalOfficial
VeltrixCapitalOfficial Jul. 2 at 2:39 PM
HIGH CONFIDENCE 🔥🚨 $RPRX 60 Call 7/17 avg .50🚨
0 · Reply
MadM
MadM Jun. 23 at 9:01 PM
$RPRX Well, it only took six years to get back. And still can't punch through that ATH ceiling.
0 · Reply
BillionerOfKing
BillionerOfKing Jun. 23 at 12:17 AM
$RPRX Current Stock Price: $53.56 Contracts to trade: $52.5 RPRX Jul 17 2026 Call Entry: $1.90 Exit: $3.44 ROI: 81% Hold ~22 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
VeltrixCapitalOfficial
VeltrixCapitalOfficial Jun. 3 at 4:14 PM
HIGH CONFIDENCE 🔥🚨 $RPRX 57.5 CALL 6/18 avg .45 🚨
0 · Reply
BillionerOfKing
BillionerOfKing May. 27 at 2:21 PM
$RPRX Current Stock Price: $54.47 Contracts to trade: $55.0 RPRX Jun 18 2026 Call Entry: $0.85 Exit: $1.16 ROI: 37% Hold ~30 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
CapitalMonk
CapitalMonk May. 25 at 8:23 PM
$RPRX Price: $54.50 (+1.77%) Trend: Bullish Market Bias (7D): Sideways ⚖️ Expected Range: ±1.27% RSI: 79.2 | Momentum: Moderate Volume: -18.4% vs avg Volatility: 1.11% Support: $48.89 | Resistance: $54.63 Sourch: http://marketbaubles.com/
0 · Reply